Table 3 Associations between use of 5α-reductase inhibitors and risk of oesophageal or cardia adenocarcinoma in stratified analyses.

From: Use of anti-androgenic 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site

Covariates

Number of cases in users/non-users

Adjusted hazard ratio (95% confidence interval)*

Interaction P value

Age, years

 <73

151/1627

0.85 (0.73–1.01)

 

 ≥73

194/1701

0.98 (0.85–1.14)

0.216

Gastro-oesophageal reflux disease

 No

312/3030

0.92 (0.82–1.04)

 

 Yes

33/298

0.86 (0.60–1.24)

0.734

Obese or diabetes

 No

314/2766

0.97 (0.87–1.10)

 

 Yes

31/562

0.55 (0.39–0.80)

0.004

Helicobacter pylori treatment

 No

335/3212

0.93 (0.83–1.04)

 

 Yes

10/116

0.65 (0.34–1.24)

0.286

Tobacco smoking or smoking-related diagnoses

 No

326/3088

0.93 (0.83–1.05)

 

 Yes

19/240

0.69 (0.43–1.09)

0.115

  1. *Adjusted for the calendar year, use of non-steroidal anti-inflammatory drugs or aspirin, use of statins, and all the other variables presented hereby.
Back to article page